Literature may not suggest unapproved conditions of use (Rx drugs)

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

In promotional communications for a prescription drug, literature, quotations, or references may not be used to recommend or suggest conditions of drug use that are not approved or permitted in the drug package labeling. This provision applies to prescription drug advertising under 21 CFR 202.1 and does not govern OTC drug materials.

Check

For a prescription drug promotional piece, check whether any cited literature, quotation, or reference is used to recommend or suggest a use, dose, population, or condition of use not found in the approved package labeling. Do not apply this check to OTC drug pieces.

Escalate when

Whether the cited literature actually implies or suggests an unapproved use requires contextual judgment about the reasonable interpretation a reader would draw.

Where this comes from

21 CFR 202.1(e)(6)(xi). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…rently favorable about a drug but fails to refer to concurrent or more recent unfavorable data or statements from the same authority on the same subject or subjects. (ix) Uses a quote or paraphrase out of context to convey a false or misleading idea. (x) Uses literature, quotations, or references that purport to support an advertising claim but in fact do not support the claim or have relevance to the claim. (xi) Uses literature, quotations, or references for the purpose of recommending or suggesting conditions of drug use that are not approved or permitted in the drug package labeling. (xii) Offers a combination of drugs for the treatment of patients suffering from a condition amenable to treatment by any of the components rather than limiting the indications for use to patients for whom concomitant therapy as provided by the fixed combination drug is indicated, unless such condition is included in the uses permitted under paragraph (e)(4) of this section. (xiii) Uses a study on normal individua…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Drug classprescription

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Faithfully tracks the quoted provision: (e)(6)(xi) is an enumerated item in the list of things that make an advertisement 'false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n)' — i.e., a per se violation, so stating it as 'may not' is not an overstatement of force. The quote is not from an example, definition, or preamble.
- Authority 'binding' is correct: this is a codified FDA regulation (21 CFR 202.1(e)(6)), not guidance.
- Determinism 'judgment' is correct: liability turns on whether the literature is used 'for the purpose of recommending or suggesting' an unapproved condition of use, which is an inference about the impression created, not a literal match.
- Atomic: a single checkable requirement (literature/quotations/references not used to suggest unapproved conditions of use). The check's mention of 'use, dose, or population' is a reasonable unpacking of 'conditions of drug use', not a bundle of independent obligations — though note dosage outside approved labeling has its own dedicated provision at (e)(6)(xvii).
- Locator 21 CFR 202.1(e)(6)(xi) matches the quoted text exactly as it appears in the source.
- Severity 'blocker' is defensible: the provision defines a per se misleading advertisement and the conduct is off-label promotion.
- Scope is broader than the source. 21 CFR 202.1(e)(6) governs advertisements for *prescription drugs* ('An advertisement for a prescription drug is false ... if it'). The rule's applies_when is an unqualified 'promotional', which would sweep in OTC materials and non-advertising promotional pieces that this provision does not reach. This limit is present in the source text and should be carried into the rule.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is operative regulatory text, not an example or preamble: it is item (xi) in the (e)(6) enumeration introduced by 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading ... if it:'. The rule statement restates it nearly verbatim and adds no element absent from the text.
- Rendering the provision as a prohibition rather than a risk is correct because (e)(6) is the per-se 'is false ... or otherwise misleading' list; the source separately reserves 'may be false ... ' for the (e)(7) list, and this rule draws from (e)(6), not (e)(7).
- applies_when is justified and appropriately limited: (e)(6) by its own terms governs advertisements for prescription drugs, matching the 'prescription' and 'promotional' tags, and the rule explicitly disclaims OTC application rather than universalizing the provision.
- Atomic: a single checkable obligation about the use of literature/quotations/references to suggest unapproved conditions of use. The check's expansion to 'use, dose, population, or condition of use' is a reasonable reading of 'conditions of drug use'; the partial overlap with the separate dosage provision at (e)(6)(xvii) does not create a second independent requirement here.
- determinism 'judgment' is correct: liability turns on whether the citation is used 'for the purpose of recommending or suggesting' an unapproved condition, which depends on reader impression and context, not a literal match. The escalation note states this accurately.
- authority 'binding' is correct (codified regulation, enforced via misbranding under section 502(n) of the act), and 'blocker' severity is defensible for a provision that deems the advertisement misleading per se; the (e)(6) waiver is petition-based and prospective and does not weaken the reviewer-facing obligation.
- Locator 21 CFR 202.1(e)(6)(xi) matches the exact position of the quoted sentence in the source text.
- Minor, non-disqualifying: the regulation's operative term is 'advertisement' while the rule opens with 'promotional communications'; the rule's own qualifier limiting it to prescription drug advertising under 21 CFR 202.1 keeps this from misstating scope.